LSTA

Business Context and Reporting Period

Company: NeoStem, Inc. (Note: Filing header lists "LISATA THERAPEUTICS, INC." but content confirms registrant is NeoStem, Inc.)
Period: Quarterly Report (Form 10-Q) for the period ended June 30, 2010.
Operations: NeoStem operates three distinct business units: (i) U.S. adult stem cell collection and storage, (ii) China adult stem cell initiatives, and (iii) China pharmaceuticals via a 51% controlling interest in Suzhou Erye Pharmaceuticals Company Ltd. ("Erye"), acquired in October 2009. Erye is a vertically-integrated manufacturer of generic antibiotics.

Key Financial Metrics

Note: 2009 figures are not directly comparable as Erye was not consolidated until October 2009. The 2010 revenue is 99% attributable to Erye pharmaceutical sales.

Material Changes vs. Prior Period

• Revenue Surge: Revenues increased from $76,738 in the prior six months to $35.2 million, driven entirely by the consolidation of Erye's pharmaceutical sales ($35.1 million). Stem cell revenues remain nominal ($66,400).
• Operating Expenses: Operating expenses increased significantly to $17.6 million (from $6.6 million) due to the inclusion of Erye's operations, increased R&D for VSEL technology, and costs associated with establishing stem cell operations in China.
• Capital Expenditures: Investing cash outflows surged to $8.0 million (from $81,000), primarily due to $8.2 million spent on the construction of Erye's new manufacturing facility and $770,000 for a Beijing stem cell laboratory.
• Financing Activity: The company raised approximately $13.6 million through public offerings and $2.6 million through warrant/option exercises. It also repaid a $2.2 million bank loan.
• Equity Structure: Series C Convertible Preferred Stock (8.2 million shares) was converted into common stock in May 2010, eliminating this class of preferred equity.

Guidance, Outlook, Risks, and Contingencies

• Liquidity Outlook: Management expects to fund operations through existing cash ($10.9 million), an equity line of credit with Commerce Court Small Cap Value Fund (up to $20 million), and limited dividends from Erye (only 6% of net profit is distributed directly to NeoStem; the rest is reinvested in Erye's facility).
• Construction Timeline: Erye's new facility is expected to be fully operational in 2011. The Beijing stem cell facility is expected to be completed by the end of 2010.
• Legal Contingencies: Erye lost a patent infringement lawsuit regarding an antibiotic product (representing <2% of sales). A judgment of approximately $750,000 (5 million RMB) was accrued, and Erye is enjoined from selling the product. Erye is appealing and negotiating a settlement.
• Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting inherited from the Erye acquisition (lack of US GAAP qualified personnel, lack of internal audit). Remediation is ongoing but not yet complete.
• Foreign Exchange Risk: Significant operations are in China; fluctuations in the Renminbi (RMB) against the USD could materially affect financial results.

Investor Verification Checklist

• Capital Needs: Verify the sufficiency of the $10.9 million cash balance and the $20 million equity line to fund the completion of the Erye facility and ongoing R&D losses.
• Dividend Restrictions: Confirm the impact of the Joint Venture Agreement which restricts 94% of Erye's net profits to be reinvested in the facility, limiting cash flow to the parent company.
• Legal Exposure: Monitor the status of the Erye patent infringement appeal and potential additional litigation risks in the Chinese pharmaceutical market.
• Internal Controls: Assess the progress of remediation for material weaknesses in financial reporting, particularly regarding US GAAP compliance at the Chinese subsidiary.
• Dilution: Review the impact of outstanding warrants (18 million shares) and options (11.8 million shares) on future share count and earnings per share.